Key Points Novo Nordisk launched its Wegovy pill in early 2026, with Eli Lilly quickly following with a pill called Foundayo. Novo Nordisk's pill has been very well received, while Eli Lilly's pill has been slower to gain traction. 10 stocks we like better than Novo Nordisk › Novo Nordisk (NYSE: NVO) was the first company to produce a GLP-1 weight-loss shot. Technically, the shot was meant for diabetics, but its ability to help people lose weight hit home with more than just diabetics. The drugmaker couldn't keep up with demand, creating an opportunity for Eli Lilly (NYSE: LLY) , which was second to market with GLP-1 shots. When Eli Lilly's drugs appeared to be more effective, it quickly took the lead in the new weight-loss niche.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.